Ecosystem
Beta Site
Search Results
16 items found for "Hypomethylating agents"
- Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia
Pamela S Becker , Tara L Lin , Sandra L Silberman , Eunice S Wang , Amer M Zeidan Tags AML , Biomarker , Hypomethylating agents , Onvansertib , PLK1 , Splicing Source Contribute to the GPCR News Coming soon Become a Contributor
- GPR37 expression as a prognostic marker in gliomas: a bioinformatics-based analysis
Finally, hypomethylation of the GPR37 promoter was associated with its high expression levels and poor
- In Silico Design of Novel RGS2-Galpha-q Interaction Inhibitors with Anticancer Activity
We sought to develop RGS2 inhibitors as potential chemotherapeutic agents utilizing structure-based drug These results highlight the potential RGS2 inhibitors have to be a new class of chemotherapeutic agents
- The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis
Brentuximab vedotin (BV), an anti-CD30 monoclonal antibody linked to a microtubule-disrupting agent, new effective combination partner of BV using non-clinical approaches that could potentially identify agents
- Ep 83 with Dr. Jean-Philippe Pin
cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic agents
- Ep 71 with Dr. Jean Martin Beaulieu
signaling and explores the potential usefulness of beta-arrestins for the development of new pharmaceutical agents
- Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia
Results: We detected genetic signatures associated with sensitivity or resistance to specific agents,
- Registration (private) | Dr. GPCR Ecosystem
see confirmation email for details *Cancel anytime *Free membership excludes personnel from US gov. agency
- Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy
As therapeutic options are limited, novel targets, and agents for therapeutic intervention are urgently
- Interrogating Multiscale Receptors Functions in Space
signaling and explores the potential usefulness of beta-arrestins for the development of new pharmaceutical agents
- Terms and Conditions | Dr. GPCR Ecosystem
applicable law, Ecosystem.DrGPCR.com (including our parent, subsidiaries, affiliates, officers, directors, agents INDEMNIFICATION: Customer agrees to indemnify, defend and hold Ecosystem.DrGPCR.com and its partners, agents
- Session II | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
His research aims to translate these novel agents to testing in clinical trials with the hope to develop
- GPCR Courses
Why are personnel from US governmental agencies excluded from the free membership? documentation during the sign-up process to confirm whether the individual is employed by a US governmental agency
- Trademark Policy | Dr. GPCR Ecosystem
Neither party shall be deemed to be an employee, agent, partner, or legal representative of the other
- Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic targets in atopic diseases
EoE , Eosinophilic esophagitis , Eosinophilic granulomatosis with polyangiitis , European Medicines Agency
- Ep 144 with Dr Aurélien Rizk
year ago and the valuable contributions of Mark Levick, a former reviewer for the European Medicines Agency
